Immunotherapy of cancer: the end of the beginning?
D003131:Combined Modality Therapy; D006801:Humans; D007116:Immunization, Passive; D007167:Immunotherapy / Q000379:methods; D007376:Interleukin-2 / Q000008:administration & dosage*; D007694:Killer Cells, Natural / Q000276:immunology*; D008213:Lymphocyte Activation; D009369:Neoplasms / Q000628:therapy*
D007376:Interleukin-2